Publications by authors named "Heidi Fraser"

Claim this Profile
T
The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).
Thomas Nittoli, Russell G Dushin, Charles Ingalls, Katherine Cheung, M Brawner Floyd, Heidi Fraser

Eur J Med Chem· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Kyung-Hee Kim, Allan Wissner, Middleton B Floyd, Heidi L Fraser, Yanong D Wang

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Allan Wissner, Heidi L Fraser, Charles L Ingalls, Russell G Dushin, M Brawner Floyd

Bioorg Med Chem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Allan Wissner, M Brawner Floyd, Bernard D Johnson, Heidi Fraser, Charles Ingalls

J Med Chem· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis